Chemical Structure (Ibrance 01)
Ibrance Tablet, Film Coated
Product Images NDC 63539-284
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Ibrance (NDC 63539-284). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by U.s. Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Ibrance 02)
Figure 2 (Ibrance 03)
Figure 3 (Ibrance 04)
The text describes a graph showing the overall survival probabilities for two treatments. One is a combination of palbociclib and fulvestrant, while the other treatment is a placebo and fulvestrant. The graph has a time axis displaying months and the probability axis displaying values from 0 to 100%. There are also the number of patients at risk displayed. Therefore, the text can be used to understand the benefits of the two treatments for medical purposes.*
Logo (Ibrance 05)
This is a statement indicating that Pfizer Labs, which is a division of Pfizer Inc, located in New York City, is the distributor of a particular product.*
Logo (Ibrance 06)
This text is a brief description of the distributor of a pharmaceutical product. It indicates that Pfizer Labs, a division of Pfizer Inc, which is located in NY, NY 10017, is responsible for distributing the product.*
Principal Display Panel (75 mg Tablet Dose Pack)
Take IBRANCE for 7 days followed by 7 days off treatment. For more information, visit www.IBRANCE.com. This is a dosage and usage guide for a 75mg blister pack of Palbociclib tablets. The tablets are distributed by US Pharmaceuticals, Pfizer Inc., NY. This is a professional sample and not for sale.*
Principal Display Panel (75 mg Tablet Dose Pack Box)
Principal Display Panel (100 mg Tablet Dose Pack)
This text provides dosage and usage information for a medication called IBRANCE, which comes in tablet form containing 100mg of palbociclib. The tablets are stored in their original blister pack and should be kept between 20-25°C (68-77°F). The recommended dose is 1 tablet per day for 21 consecutive days, followed by 7 days off treatment. This information is intended for medical professionals and is not a product for sale to the public. For more information, go to the website www.jibrance.com.*
Principal Display Panel (100 mg Tablet Dose Pack Box)
Principal Display Panel (125 mg Tablet Dose Pack)
Take IBRANCE for seven days followed by seven days off treatment. Dosage and usage information can be found in the accompanying prescribing and patient information. Each tablet contains 125mg of palbociclib and should be stored in the original blister pack between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). IBRANCE is distributed by US Pharmaceuticals in NY. This is a professional sample and not for sale.*
Principal Display Panel (125 mg Tablet Dose Pack Box)
The text is describing a medication named IBRANCE (palbociclib) in the form of tablets of dosage 125mg. It comes in a month box consisting of weekly packs, each pack comprising of 7 IBRANCE tablets. The rest of the text consists of alphanumeric codes that are not clear or readable.*
Principal Display Panel (Topper Card)
Your Monthly Box includes three weekly packs of IBRANCE medication. You can use the given tracker to fill in the dates to help track your treatment cycle. The tracker consists of three weeks, and you need to fill in the months and days for the start of the first and fourth week.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
